This November, Lambda Biologics will participate in the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, joining researchers and innovators from around the world who are advancing the future of immuno-oncology. At our booth, with the theme “Personalizing TME with Organoid”, we will share our latest work in building organoid-based tumor microenvironment (TME) models – a step toward making cancer research more predictive, more human, and ultimately more hopeful for patients.
Immunotherapy has transformed how we treat cancer, yet translating promising preclinical results into consistent clinical benefit remains one of oncology’s greatest challenges. The reason often lies in the limitations of traditional models, which fail to capture the full complexity of the TME – the living ecosystem that shapes how tumors grow, evade, and respond to treatment.
Personalizing TME with Organoid
At Lambda Biologics, we believe that understanding and recreating this environment is key to designing more effective therapies. Tumors are not isolated cell clusters; they exist within a complex network of fibroblasts, immune cells, and extracellular matrix components that continuously interact and influence disease progression. When these interactions are missing, preclinical predictions lose their power.
Even advanced organoid models have historically lacked critical elements of the microenvironment – such as Cancer-Associated Fibroblasts (CAFs), Tumor-Infiltrating Lymphocytes (TILs), macrophages, cytotoxic T cell and regulatory T cells – cells that play decisive roles in how tumors respond to immunotherapy. Without them, preclinical systems cannot fully reflect the biology that determines patient outcomes.
Lambda Biologics integrates these components into patient-derived organoids to reconstruct functional, living TMEs. These models allow researchers to observe immune-tumor interactions, assess therapeutic responses, and explore mechanisms of resistance in a context that mirrors human biology. Our goal is not to help tumors grow – but to help therapies outsmart them.
This effort reflects a shared mission across the scientific community: to bridge the gap between preclinical discovery and clinical reality. Every advance brings us closer to therapies that are not only innovative, but also truly meaningful to patients and their families.
Join us at SITC2025, Booth 420, to explore how human-relevant TME models can transform immuno-oncology research and shape the next generation of cancer therapy.
SITC2025 – Event Detail:
- Time: November 05 – 09, 2025
- Location: National Harbor, Maryland, USA
- Event website: https://www.sitcancer.org/2025/home
- Lambda Biologics Booth: 420
For more information, contact us at: info@lambdabiologics.com
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
